Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy

NCT00336856 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Colon Cancer
Rectum Cancer

Interventions

DRUG: Cetuximab
DRUG: Irinotecan

Sponsor

University of Pittsburgh

Collaborators

[object Object]